Literature DB >> 25199774

Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.

Dong Sik Jung1, Frank P Tverdek2, Dimitrios P Kontoyiannis3.   

Abstract

We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25199774      PMCID： PMC4249440          DOI： 10.1128/AAC.04035-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Relevance of timing for determination of posaconazole plasma concentrations.

Authors:  Werner J Heinz; Janina Zirkel; Anna Kuhn; Diana Schirmer; Ulrike Lenker; Daniela Keller; Hartwig Klinker
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

2.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

3.  Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.

Authors:  Gopal Krishna; Lei Ma; Monika Martinho; Edward O'Mara
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

4.  Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

Authors:  Walter K Kraft; Peter S Chang; Marlou L P S van Iersel; Hetty Waskin; Gopal Krishna; Wendy M Kersemaekers
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

5.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

6.  A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma.

Authors:  Jim X Shen; Gopal Krishna; Roger N Hayes
Journal:  J Pharm Biomed Anal       Date:  2006-07-21       Impact factor: 3.935

Review 7.  Fungal infections in leukemia patients: how do we prevent and treat them?

Authors:  Konstantinos Leventakos; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring.

Authors:  Marie-Rose B S Crombag; Cynthia Huisman; Elles M Kemper; Roger J M Brüggemann; Yuma A Bijleveld
Journal:  Ther Drug Monit       Date:  2012-06       Impact factor: 3.681

Review 9.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790

10.  A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.

Authors:  G Krishna; L Ma; M Martinho; R A Preston; E O'Mara
Journal:  J Antimicrob Chemother       Date:  2012-07-24       Impact factor: 5.790
  10 in total
  38 in total

Review 1.  Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Authors:  Anna B Halpern; Gary H Lyman; Thomas J Walsh; Dimitrios P Kontoyiannis; Roland B Walter
Journal:  Blood       Date:  2015-10-26       Impact factor: 22.113

2.  Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.

Authors:  Elodie Gautier-Veyret; Léa Bolcato; Matthieu Roustit; Stéphanie Weiss; Julia Tonini; Marie-Pierre Brenier-Pinchart; Muriel Cornet; Anne Thiebaut-Bertrand; Françoise Stanke-Labesque
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.

Authors:  Frank P Tverdek; Sang Taek Heo; Samuel L Aitken; Bruno Granwehr; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 4.  Antifungal stewardship considerations for adults and pediatrics.

Authors:  Rana F Hamdy; Theoklis E Zaoutis; Susan K Seo
Journal:  Virulence       Date:  2016-09-02       Impact factor: 5.882

5.  Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.

Authors:  A Petitcollin; C Boglione-Kerrien; C Tron; S Nimubona; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 6.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia.

Authors:  George R Thompson; Diana Chang; Rebecca R Wittenberg; Ian McHardy; Alison Semrad
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 8.  Pharmacologic and clinical evaluation of posaconazole.

Authors:  Jason N Moore; Jason R Healy; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2015-05       Impact factor: 5.045

9.  Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort.

Authors:  George R Thompson; Charles R Krois; Verena K Affolter; Angela D Everett; E Katarina Varjonen; Victoria R Sharon; Anil Singapuri; Michael Dennis; Ian McHardy; Hong Sik Yoo; Dawn M Fedor; Nathan P Wiederhold; Phylicia A Aaron; Angie Gelli; Joseph L Napoli; Stephen D White
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.